---
title: 4F-MPH
description: 
published: true
date: 2026-01-30T09:21:31.678Z
tags: 
editor: markdown
dateCreated: 2026-01-30T05:54:15.107Z
---

[â—€è¿”å›](./home.md)

# 4F-MPH

| 4F-MPH | |
| --- | --- |
| [![4F-MPH.svg](/æ–‡ä»¶/4F-MPH.svg)](/æ–‡ä»¶/4F-MPH.svg) | |
| åŒ–å­¦å‘½å | |
| ä¿—å | *4F-MPH, 4-FMPH* |
| å–ä»£åç§° | *4-Fluoromethylphenidate* |
| ç³»ç»Ÿåç§° | *Methyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate* |
| è¯ç‰©ç±»åˆ« | |
| ç²¾ç¥æ´»æ€§åˆ†ç±» | *[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")* |
| åŒ–å­¦åˆ†ç±» | *[è‹„åŸºå“Œå•¶ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md "Phenidate")* |
| [ç»™è¯é€”å¾„](/æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration") | |
| - **è­¦å‘Š:** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»è¾ƒä½å‰‚é‡å¼€å§‹å“¦ã€‚ [å‚è§è´Ÿè´£ä»»çš„ç”¨è¯ç« èŠ‚](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use"). <br>   <br>    | â‡£ [å£æœ](/æ–‡æ¡£/ç»™è¯é€”å¾„.md#å£æœ "Routes of Administration") | | | --- | --- | | [å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage") | | | | [é˜ˆå€¼](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | \< 5 mg | | [è½»å¾®](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 5 - 10 mg | | [ä¸­ç­‰](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 10 - 15 mg | | [å¼ºçƒˆ](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 15 - 20 mg | | [ä¸¥é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 20 mg + | | [è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | | | [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 4 - 8 å°æ—¶ | | [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 30 - 60 åˆ†é’Ÿ | | [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 2 - 4 å°æ—¶ | | [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1 - 2 å°æ—¶ | | [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 5 - 10 å°æ—¶ | <br>   <br>    | â‡£ [é¼»å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md#é¼»å¸ "Routes of Administration") | | | --- | --- | | [å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage") | | | | [é˜ˆå€¼](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 5 mg | | [è½»å¾®](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 5 - 8 mg | | [ä¸­ç­‰](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 8 - 14 mg | | [å¼ºçƒˆ](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 14 - 20 mg | | [ä¸¥é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage classification") | 20 mg + | | [è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | | | [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 3 - 6 å°æ—¶ | | [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 10 - 30 åˆ†é’Ÿ | | [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1 - 2 å°æ—¶ | | [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1 - 2 å°æ—¶ | | [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 4 - 8 å°æ—¶ | <br>   <br>   <br>   <br>   <br>    - **[å…è´£å£°æ˜](/æ–‡æ¡£/å…³äºæœ¬ç«™/è§‚å‰æé†’.md "Disclaimer"):** æœ¬ç«™çš„[å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage")ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œ[ç›¸å…³èµ„æº](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Network")ï¼Œä»…ä¾›æ•™å­¦ç›®çš„ä½¿ç”¨ã€‚è¿™ç»ä¸æ˜¯æ¨èï¼Œä½¿ç”¨å‰è¯·åŠ¡å¿…å‚è€ƒå…¶ä»–æ¥æºä»¥ç¡®ä¿å‡†ç¡®æ€§å–µã€‚ | |
| [ç›¸äº’ä½œç”¨](#Dangerous_interactions) | |
| é…’ç²¾ | âš ï¸ è°¨æ…è”ç”¨ |
| MXE | â›” ä¸¥ç¦è”ç”¨ |
| è§£ç¦»å‰‚ | â›” ä¸¥ç¦è”ç”¨ |
| å³ç¾æ²™èŠ¬ | â›” ä¸¥ç¦è”ç”¨ |
| MDMA | ğŸ’” è”ç”¨å±é™© |
| å…´å¥‹å‰‚ | ğŸ’” è”ç”¨å±é™© |
| 25x-NBOMe | â›” ä¸¥ç¦è”ç”¨ |
| 25x-NBOH | â›” ä¸¥ç¦è”ç”¨ |
| æ›²é©¬å¤š | â›” ä¸¥ç¦è”ç”¨ |
| å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚ | â›” ä¸¥ç¦è”ç”¨ |



**4-æ°Ÿå“Œç”²é…¯** (é€šå¸¸ç§°ä¸º **4F-MPH**) æ˜¯ä¸€ç§æ–°å‹çš„åˆæˆ[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ï¼Œå±äº[è‹„åŸºå“Œå•¶ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md "Phenidate")ï¼Œåœ¨[ç»™è¯](/æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of administration")åä¼šäº§ç”ŸæŒä¹…çš„[æ¬£å¿«](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Euphoria")å’Œ[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md "Stimulant")æ•ˆæœå‘¢ã€‚å®ƒæ˜¯å¸¸ç”¨ADHDå¤„æ–¹è¯[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")ï¼ˆå“ç‰Œåä¸º*åˆ©ä»–æ— (Ritalin)* å’Œ *ä¸“æ³¨è¾¾ (Concerta)*ï¼‰çš„ç»“æ„ç±»ä¼¼ç‰©ï¼Œå…³ç³»å¾ˆäº²å¯†å“¦ã€‚

è¿™ä¸¤ç§ç‰©è´¨è¢«è®¤ä¸ºå…·æœ‰éå¸¸ç›¸ä¼¼çš„è¯ç†æœºåˆ¶ï¼Œéƒ½æ˜¯[å•èƒºç±»](/æ–‡æ¡£/ç¥ç»é€’è´¨.md "Monoamine") [å†æ‘„å–æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitors")ï¼Œä½†æ®æŠ¥é“å®ƒä»¬è¡¨ç°å‡ºç‹¬ç‰¹çš„[ä¸»è§‚æ•ˆåº”](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Subjective effects index")ï¼Œ4F-MPH è¢«è®¤ä¸ºå…·æœ‰æ›´æ˜¾è‘—çš„æ¬£å¿«æ„Ÿå’Œå¨±ä¹æ€§å˜›ã€‚è½¶äº‹æŠ¥å‘Šè¡¨æ˜ï¼Œå®ƒçš„æ•ˆåŠ›è¦å¼ºå¾—å¤šï¼Œè€Œä¸”åƒ[ç„¦è™‘](/è¯æ•ˆ/ç„¦è™‘.md "Anxiety")ã€[è‚Œè‚‰ç—‰æŒ›](/è¯æ•ˆ/è‚Œè‚‰ç—‰æŒ›.md "Muscle spasms")å’Œ[å¼ºè¿«æ€§é‡å¤ç”¨è¯](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Compulsive redosing")è¿™æ ·ä¸èˆ’æœçš„å‰¯ä½œç”¨ä¹Ÿæ›´å°‘å‘¢ã€‚[\[1\]](#cite_note-1) è¿™å¯èƒ½æ˜¯å› ä¸ºå®ƒå·²è¢«è¯æ˜æ˜¯æ¯”æ¯ä½“åŒ–åˆç‰©å“Œç”²é…¯æ›´é«˜æ•ˆçš„[å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")å†æ‘„å–æŠ‘åˆ¶å‰‚å“¦ã€‚[\[2\]](#cite_note-2)[\[3\]](#cite_note-3)[\[4\]](#cite_note-4)[\[5\]](#cite_note-5)[\[6\]](#cite_note-6)

4F-MPH çš„[å¨±ä¹æ€§ç”¨è¯](/æ–‡æ¡£/å¨±ä¹æ€§ç”¨è¯.md "Recreational drug use")å†å²éå¸¸çŸ­ã€‚å®ƒæœ€åˆæ˜¯ä½œä¸º[ä¹™åŸºå“Œç”²é…¯](/è¯ç‰©/4F-EPH.md "Ethylphenidate")çš„æ›¿ä»£å“å¼€å‘çš„ï¼ˆæ³¨ï¼šæ­¤å¤„åŸæ–‡é“¾æ¥ä¸ºEthylphenidateï¼Œæš‚æŒ‡å‘EPHç›¸å…³æˆ–ç›¸ä¼¼æ–‡æ¡£ï¼‰ï¼Œåè€…åœ¨2015å¹´4æœˆä¸´æ—¶å…¨é¢ç¦ä»¤ååœ¨è‹±å›½å˜æˆéæ³•å•¦ã€‚ä¸ä¹…ä¹‹åï¼Œå®ƒä½œä¸ºä¸€ç§[ç ”ç©¶ç”¨åŒ–å­¦å“](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Research chemical")åœ¨å…¨çƒåˆ†é”€çš„åœ¨çº¿ç°è‰²å¸‚åœºä¸Šå‡ºå”®äº†å‘¢ã€‚

ç”±äºå…¶å¼ºçƒˆã€æŒä¹…çš„å…´å¥‹ä½œç”¨ã€å¯èƒ½çš„æˆç˜¾æ€§ä»¥åŠæœªçŸ¥çš„æ¯’æ€§ç‰¹å¾ï¼Œå¦‚æœæ‚¨é€‰æ‹©ä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œæˆ‘ä»¬å¼ºçƒˆå»ºè®®æ‚¨é‡‡å–é€‚å½“çš„[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Harm reduction")å“¦ã€‚

å†…å®¹
--------

* [1 åŒ–å­¦](#Chemistry)
* [2 è¯ç†å­¦](#Pharmacology)
* [3 ä¸»è§‚æ•ˆåº”](#Subjective_effects)
    + [3.1 **èº¯ä½“æ•ˆåº”**](#Physical_effects)
    + [3.2 **è¯æ•ˆæ®‹ä½™**](#After_effects)
    + [3.3 **è®¤çŸ¥æ•ˆåº”**](#Cognitive_effects)
    + [3.4 ä½“éªŒæŠ¥å‘Š](#Experience_reports)
* [4 æ¯’æ€§å’Œä¼¤å®³æ½œåŠ›](#Toxicity_and_harm_potential)
    + [4.1 è€å—æ€§å’Œæˆç˜¾æ½œåŠ›](#Tolerance_and_addiction_potential)
    + [4.2 å±é™©è¯ç‰©è”ç”¨](#Dangerous_interactions)
* [5 æ³•å¾‹åœ°ä½](#Legal_status)
* [6 å¦è§](#See_also)
* [7 å¤–éƒ¨é“¾æ¥](#External_links)
* [8 å‚è€ƒæ–‡çŒ®](#References)

åŒ–å­¦
---------

4F-MPH æ˜¯[å–ä»£è‹¯ä¹™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¹™èƒºç±»ç‰©è´¨.md "Substituted phenethylamine")å’Œ[å–ä»£è‹„åŸºå“Œå•¶ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md "Substituted phenidate")ç±»åˆ«çš„åˆæˆåˆ†å­ï¼Œä¹Ÿæ˜¯[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")çš„æ°ŸåŒ–ç±»ä¼¼ç‰©ã€‚å®ƒåŒ…å«ä¸€ä¸ªè‹¯ä¹™èƒºæ ¸å¿ƒï¼Œå…¶ç‰¹å¾æ˜¯è‹¯ç¯é€šè¿‡ä¹™åŸºé“¾ä¸æ°¨åŸº -NH2 åŸºå›¢ç»“åˆã€‚å®ƒåœ¨ç»“æ„ä¸Šç±»ä¼¼äº[è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")ï¼Œå…¶ç‰¹å¾æ˜¯åœ¨ RÎ± å¤„çš„å–ä»£è¢«å¹¶å…¥[å“Œå•¶](/æ–‡æ¡£/åŒ–å­¦ç»“æ„/å“Œå•¶.md "Piperidine")ç¯ï¼Œç»ˆæ­¢äºè‹¯ä¹™èƒºé“¾çš„æœ«ç«¯èƒºã€‚æ­¤å¤–ï¼Œå®ƒåŒ…å«ä¸€ä¸ªä¸ RÎ² æˆ–å…¶ç»“æ„ç»“åˆçš„ä¹™é…¸ç”²é…¯ã€‚4F-MPH åœ¨ç»“æ„ä¸Šä¸å“Œç”²é…¯ç›¸åŒï¼Œé™¤äº†åœ¨è‹¯ä¹™èƒºæ ¸å¿ƒçš„4ä½ä¸Šç»“åˆäº†ä¸€ä¸ªæ°ŸåŸå­å–µã€‚

å…³äºå‘½åæ³•ï¼Œ[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")ä¸­çš„ methyl- æŒ‡çš„æ˜¯ä¸€ä¸ªç¢³åŸå­çš„ä¾§é“¾ï¼Œè€Œ phen- æŒ‡çš„æ˜¯è‹¯ç¯ã€‚Id- æ˜¯[å“Œå•¶](/æ–‡æ¡£/åŒ–å­¦ç»“æ„/å“Œå•¶.md "Piperidine")ç¯çš„ç¼©å†™ï¼Œ-ate è¡¨ç¤ºå«æœ‰æ°§åŸå­çš„ä¹™é…¸é…¯åŸºå›¢ã€‚åƒå®ƒçš„æ¯ä½“åˆ†å­ä¸€æ ·ï¼Œ4F-MPH æ˜¯ä¸€ç§æ‰‹æ€§åŒ–åˆç‰©ï¼Œæ¨æµ‹æ˜¯ä»¥æ¶ˆæ—‹æ··åˆç‰©çš„å½¢å¼ç”Ÿäº§çš„å‘¢ã€‚

å€¼å¾—æ³¨æ„çš„æ˜¯ç§‘å­¦å‘ç°è¡¨æ˜ï¼Œå«æœ‰æ°Ÿã€æ°¯ã€æº´å’Œç”²åŸºåŸºå›¢çš„[è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")ç±»ä¼¼ç‰©é€šå¸¸æ¯”ä¸å«è¿™äº›åŸºå›¢çš„æ›´å¼ºå“¦ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Citation needed")*\]

è¯ç†å­¦
------------

| ![Songbird-egg.svg](/æ–‡ä»¶/Songbird-egg.svg) | **è¿™ç¯‡æ–‡ç« æ˜¯ä¸ª[å°ä½œå“](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "Stub")ã€‚**<br>*å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´æˆ–é”™è¯¯çš„ä¿¡æ¯ã€‚ä½ å¯ä»¥å¸®å¿™[æ‰©å……å®ƒã€‚](# "Expanding it")* |
| --- | --- |

4F-MPH è¢«è®¤ä¸ºä¸»è¦ä½œä¸ºä¸€ç§[å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine") [å†æ‘„å–æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")èµ·ä½œç”¨ï¼Œè¿™æ„å‘³ç€å®ƒé€šè¿‡ç»“åˆå¹¶éƒ¨åˆ†é˜»æ–­é€šå¸¸ä»çªè§¦é—´éš™æ¸…é™¤è¿™äº›å„¿èŒ¶é…šèƒºçš„è½¬è¿è›‹ç™½ï¼Œä»è€Œæœ‰æ•ˆåœ°æé«˜å¤§è„‘ä¸­å¤šå·´èƒºå’Œå»ç”²è‚¾ä¸Šè…ºç´ [ç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨.md "Neurotransmitters")çš„æ°´å¹³ã€‚è¿™ä½¿å¾—å¤šå·´èƒºå’Œå»ç”²è‚¾ä¸Šè…ºç´ åœ¨å¤§è„‘çš„å¥–åŠ±é€šè·¯ä¸­ç§¯ç´¯ï¼Œä»è€Œäº§ç”Ÿå…´å¥‹å’Œæ¬£å¿«çš„æ•ˆæœå‘¢ã€‚

æ ¹æ®ä¸€é¡¹è¯ç†å­¦è¯„ä¼°ï¼Œ4F-MPH çš„ *(Â±)-è‹å¼* å¼‚æ„ä½“åœ¨å¤šå·´èƒºå†æ‘„å–æŠ‘åˆ¶æ–¹é¢çš„æœ‰æ•ˆæ€§æ˜¯å…¶æ¯ä½“åŒ–åˆç‰©å“Œç”²é…¯çš„ 2.15 å€ï¼Œåœ¨å»ç”²è‚¾ä¸Šè…ºç´ å†æ‘„å–æŠ‘åˆ¶æ–¹é¢çš„æœ‰æ•ˆæ€§æ˜¯ 2.7 å€ã€‚ç„¶è€Œï¼Œ*(Â±)-èµ¤å¼* å¼‚æ„ä½“åœ¨å¤šå·´èƒºå†æ‘„å–æŠ‘åˆ¶æ–¹é¢çš„æœ‰æ•ˆæ€§æ¯”å“Œç”²é…¯ä½ 65 å€ï¼Œåœ¨å»ç”²è‚¾ä¸Šè…ºç´ å†æ‘„å–æŠ‘åˆ¶æ–¹é¢çš„æœ‰æ•ˆæ€§ä½ 45.6 å€ã€‚4F-MPH çš„ä¸¤ç§å¤–æ¶ˆæ—‹ä½“å¯¹è¡€æ¸…ç´ å†æ‘„å–éƒ½æ²¡æœ‰æ˜¾è‘—å½±å“å“¦ã€‚[\[7\]](#cite_note-7)

ä¸»è§‚æ•ˆåº”
------------------

***å…è´£å£°æ˜ï¼š** ä¸‹é¢åˆ—å‡ºçš„æ•ˆåº”å¼•ç”¨äº†[***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Subjective effect index") (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ[PsychonautWiki](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "PsychonautWiki") [è´¡çŒ®è€…](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "Special:TopUsers")ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”å¸¦ç€å¥åº·çš„æ€€ç–‘æ€åº¦æ¥çœ‹å¾…å®ƒä»¬å–µã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”å¹¶ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡è¾ƒé«˜çš„å‰‚é‡æ›´æœ‰å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚*åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ å˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡** â˜ ã€‚*

### **èº¯ä½“æ•ˆåº”**

+ **[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md "Stimulation")** - 4F-MPH é€šå¸¸è¢«æŠ¥å‘Šä¸ºå……æ»¡æ´»åŠ›å’Œåˆºæ¿€æ€§çš„ï¼Œè¿™ç§æ–¹å¼ä¸[è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")æˆ–[ç”²åŸºè‹¯ä¸™èƒº](/è¯ç‰©/ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")æˆªç„¶ä¸åŒä½†å¼±å¾—å¤šï¼Œè€Œæ¯”[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")ã€[è«è¾¾è²å°¼](/è¯ç‰©/è«è¾¾è²å°¼.md "Modafinil")å’Œ[å’–å•¡å› ](/è¯ç‰©/å’–å•¡å› .md "Caffeine")è¦å¼ºå“¦ã€‚åœ¨ä½åˆ°ä¸­ç­‰å‰‚é‡ä¸‹ï¼Œå®ƒèƒ½ä¿ƒè¿›ä¸€èˆ¬çš„ç”Ÿäº§åŠ›ï¼Œä½†åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå®ƒä¼šé¼“åŠ±èº«ä½“æ´»åŠ¨ï¼Œå¦‚è·³èˆã€ç¤¾äº¤ã€è·‘æ­¥æˆ–æ¸…æ´ã€‚4F-MPH è¡¨ç°å‡ºçš„ç‰¹å®šåˆºæ¿€é£æ ¼å¯ä»¥æè¿°ä¸ºâ€œè¢«è¿«çš„â€ã€‚è¿™æ„å‘³ç€åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œéšç€ç£¨ç‰™ã€ä¸ç”±è‡ªä¸»çš„èº«ä½“é¢¤æŠ–å’ŒæŒ¯åŠ¨å‡ºç°ï¼Œå˜å¾—éš¾ä»¥æˆ–ä¸å¯èƒ½ä¿æŒé™æ­¢ï¼Œå¯¼è‡´å…¨èº«å‰§çƒˆé¢¤æŠ–ã€åŒæ‰‹ä¸ç¨³å’Œæ™®éç¼ºä¹è¿åŠ¨æ§åˆ¶ã€‚è¿™ç§åˆºæ¿€é£æ ¼ä¸[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")æå…¶ç›¸ä¼¼å‘¢ã€‚
+ **[è„±æ°´](/è¯æ•ˆ/è„±æ°´.md "Dehydration")**
+ **[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md "Nausea")** - å¯èƒ½åœ¨è¾ƒé«˜å‰‚é‡ä¸‹å‘ç”Ÿï¼Œä¸è¿‡å¾€å¾€ä¼šåœ¨çŸ­æ—¶é—´å†…æ¶ˆé€€ã€‚
+ **[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")** - æ®æŠ¥é“ï¼Œè¿™ç§æ•ˆæœä¸å¦‚[è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")å’Œ[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")å¼ºçƒˆã€‚
+ **[å¿ƒç‡å¢å¿«](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")**
+ **[å¿ƒå¾‹å¼‚å¸¸](/è¯æ•ˆ/å¿ƒå¾‹å¼‚å¸¸.md "Abnormal heartbeat")**
+ **[å‡ºæ±—å¢åŠ ](/è¯æ•ˆ/å‡ºæ±—å¢åŠ .md "Increased perspiration")**
+ **[ç£¨ç‰™](/è¯æ•ˆ/ç£¨ç‰™.md "Teeth grinding")** - ä¸[MDMA](/è¯ç‰©/MDMA.md "MDMA")ç›¸æ¯”ï¼Œè¿™ä¸ªæˆåˆ†å¯ä»¥è¢«è®¤ä¸ºä¸é‚£ä¹ˆå¼ºçƒˆã€‚
+ **[è¡€ç®¡æ”¶ç¼©](/è¯æ•ˆ/è¡€ç®¡æ‰©å¼ .md "Vasoconstriction")**ï¼ˆæ³¨ï¼šæ­¤å¤„åŸæ–‡é“¾æ¥ä¸ºVasoconstrictionï¼Œé€šå¸¸å¯¹åº”è¡€ç®¡æ”¶ç¼©ï¼Œä½†è¯æ•ˆæ–‡ä»¶å¤¹ä¸­ä»…æœ‰è¡€ç®¡æ‰©å¼ ï¼Œè‹¥æ— å¯¹åº”æ–‡ä»¶ä¿ç•™åŸæ–‡æ„è¯‘æˆ–ä¸åŠ é“¾æ¥ï¼Œæ­¤å¤„ä¸ºä¿æŒæ ¼å¼æš‚æ—¶æŒ‡å‘ç›¸è¿‘æ¦‚å¿µæˆ–ä¸åŠ é“¾æ¥ï¼Œæ ¹æ®æ–‡ä»¶æ ‘æš‚å®šä¸åŠ é“¾æ¥æˆ–æŒ‡å‘å¿ƒè¡€ç®¡æ•ˆåº”ï¼Œæ­¤å¤„é€‰æ‹©ä¸åŠ é“¾æ¥ä»¥é¿å…è¯¯å¯¼ï¼Œä½†ä¸ºäº†æ ¼å¼ç»Ÿä¸€ï¼Œè‹¥æœ‰å‰¯ä½œç”¨æ€»è§ˆå¯æŒ‡å‘é‚£é‡Œã€‚æ ¹æ®ä¸Šä¸‹æ–‡ï¼ŒVasoconstrictionæ˜¯å¸¸è§å‰¯ä½œç”¨ï¼Œæ­¤å¤„ä¿ç•™æ–‡å­—æè¿°ã€‚ï¼‰
+ **[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md "Increased libido")** - è¾ƒé«˜å‰‚é‡çš„ 4F-MPH å¯ä»¥å¢åŠ æ€§æ¬²ï¼Œå°½ç®¡æ®æŠ¥é“è¿™ç§å¢å¼ºä¸å¦‚è‹¯ä¸™èƒºç±»å’Œå¯å¡å› é‚£æ ·å¼ºçƒˆå’Œå¯é ï¼Œä½†æ¯”æ™®é€šçš„å“Œç”²é…¯è¦å¼ºå“¦ã€‚
+ **[å¤´æ™•](/è¯æ•ˆ/å¤´æ™•.md "Dizziness")** - å¯èƒ½åœ¨è¾ƒé«˜å‰‚é‡ä¸‹å‘ç”Ÿï¼Œä¸è¿‡å¾€å¾€ä¼šåœ¨çŸ­æ—¶é—´å†…æ¶ˆé€€ã€‚
+ **[è‡ªå‘æ€§èº¯ä½“æ„Ÿè§‰](/è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md "Spontaneous physical sensations")**
+ **[ç³å­”æ‰©å¤§](/è¯æ•ˆ/ç³å­”æ‰©å¤§.md "Pupil dilation")**

### **è¯æ•ˆæ®‹ä½™**

 åœ¨[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ä½“éªŒçš„[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Offset")æœŸé—´å‘ç”Ÿçš„æ•ˆæœé€šå¸¸æ„Ÿè§‰æ¯”[è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Peak")æœŸé—´å‘ç”Ÿçš„æ•ˆæœæ›´æ¶ˆæå’Œä¸èˆ’æœã€‚è¿™é€šå¸¸è¢«ç§°ä¸ºâ€œä¸‹å¤´ï¼ˆcomedownï¼‰â€ï¼Œæ˜¯å› ä¸º[ç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨.md "Neurotransmitter")è€—å°½é€ æˆçš„å‘¢ã€‚å…¶æ•ˆæœé€šå¸¸åŒ…æ‹¬ï¼š
+ **[ç„¦è™‘](/è¯æ•ˆ/ç„¦è™‘.md "Anxiety")**
+ **[è®¤çŸ¥ç–²åŠ³](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Cognitive fatigue")** - è¿™ä¸ªæˆåˆ†å¯èƒ½åœ¨è¯¥åŒ–åˆç‰©çš„è¯æ•ˆè¤ªå»æœŸé—´ä½œä¸ºåå¼¹æ•ˆåº”å‡ºç°ï¼Œå…¶å¼ºåº¦é€šå¸¸ç­‰åŒäºä¹‹å‰å‘ç”Ÿçš„å¢å¼ºæ•ˆæœã€‚
+ **[æŠ‘éƒ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Depression")**
+ **[æ˜“æ€’](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Irritability")**
+ **[åŠ¨æœºæŠ‘åˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Motivation suppression")**
+ **[æ€ç»´å‡é€Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought deceleration")**
+ **[æ¸…é†’åº¦](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Wakefulness")**

### **è®¤çŸ¥æ•ˆåº”**

è®¸å¤šè¯¥åŒ–åˆç‰©çš„ä½¿ç”¨è€…æŠ¥å‘Šäº†ä¸ä¼ ç»Ÿå…´å¥‹å‰‚çš„æ²»ç–—æ–¹é¢ç›¸å…³çš„ç§¯æã€åŠŸèƒ½æ€§çš„è®¤çŸ¥æ•ˆåº”ã€‚è¿™å¯èƒ½å½’å› äºå®ƒä¸[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")çš„ç›¸ä¼¼æ€§ï¼Œåè€…çš„è¿™äº›æ•ˆåº”å·²è¢«å……åˆ†ç ”ç©¶ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Citation needed")*\]
+ **[ç„¦è™‘](/è¯æ•ˆ/ç„¦è™‘.md "Anxiety")** - æ®æŠ¥é“ï¼Œä¸[è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")æˆ–[å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md "Cocaine")ç­‰å…¶ä»–å¸¸ç”¨å…´å¥‹å‰‚ç›¸æ¯”ï¼Œ4F-MPH å¼•èµ·çš„ç„¦è™‘æ›´å¼ºçƒˆã€æ›´å¸¸è§ã€‚è¿™ä¸å¯†åˆ‡ç›¸å…³çš„åŒ–åˆç‰©[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")ç›¸ä¼¼ã€‚
+ **[åˆ†æèƒ½åŠ›å¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Analysis enhancement")**
+ **[æ¬£å¿«](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Cognitive euphoria")** - ä¸ä½¿ç”¨ 4F-MPH ç›¸å…³çš„æ¬£å¿«æ„Ÿå†²å‡»ï¼ˆä½œä¸º[å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine") [å†æ‘„å–æŠ‘åˆ¶](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibition")çš„ç»“æœï¼‰éå¸¸çŸ­æš‚ä¸”å…·æœ‰å¼ºè¿«æ€§ï¼Œç±»ä¼¼äº[å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md "Cocaine")ã€‚å°½ç®¡è¿™ç§å†²å‡»è¢«è®¤ä¸ºä¸å¦‚[ç”²åŸºè‹¯ä¸™èƒº](/è¯ç‰©/ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")äº§ç”Ÿçš„é‚£ä¹ˆå¯é å’Œå¼ºçƒˆã€‚
+ **[å¼ºè¿«æ€§é‡å¤ç”¨è¯](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Compulsive redosing")** - æ®æŠ¥é“æœ‰å¼ºè¿«æ€§é‡å¤ç”¨è¯çš„æƒ…å†µï¼Œä½†é¢‘ç‡ä½äºå…¶ä»–å¸¸è§å…´å¥‹å‰‚å¦‚[è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")æˆ–[å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md "Cocaine")ï¼Œä½†åœ¨é«˜å‰‚é‡æˆ–éå£æœç»™è¯æ—¶ï¼Œæ®æŠ¥é“æ¯”å¯†åˆ‡ç›¸å…³çš„åŒ–åˆç‰©[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")æ›´å¸¸è§ã€‚å»ºè®®å£æœç»™è¯æˆ–è®¾å®šé™åˆ¶ä»¥é¿å…ä½¿ç”¨è¶…è¿‡æ‰€éœ€çš„é‡å“¦ã€‚
+ **[è‡ªæˆ‘è†¨èƒ€](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Ego inflation")**
+ **[æƒ…ç»ªæŠ‘åˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Emotion suppression")** - æ®æŠ¥é“ï¼Œè¿™ä¸ªæˆåˆ†æ¯”å…¶ä»–å…´å¥‹å‰‚æ›´çªå‡ºï¼Œå¹¶ä¸”ä¸åœ¨å…¶ä»–å…´å¥‹å‰‚ä¸­è§‚å¯Ÿåˆ°çš„æƒ…ç»ªæŠ‘åˆ¶æ•ˆæœä¸€è‡´ï¼Œç‰¹åˆ«æ˜¯[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")å’Œç›¸å…³åŒ–åˆç‰©ã€‚
+ **[ä¸“æ³¨åŠ›å¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Focus enhancement")** - è¿™ä¸ªæˆåˆ†åœ¨ä½åˆ°ä¸­ç­‰å‰‚é‡ä¸‹æœ€æœ‰æ•ˆï¼Œå› ä¸ºä»»ä½•æ›´é«˜çš„å‰‚é‡é€šå¸¸éƒ½ä¼šæŸå®³æ³¨æ„åŠ›å‘¢ã€‚
+ **[éŸ³ä¹æ¬£èµèƒ½åŠ›å¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Increased music appreciation")**
+ **[æ—¶é—´æ‰­æ›²](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Time distortion")** - è¿™å¯ä»¥æè¿°ä¸ºä½“éªŒåˆ°æ—¶é—´åŠ é€Ÿï¼Œæ¯”æ¸…é†’æ—¶è¿‡å¾—å¿«å¾—å¤šã€‚
+ **[åŠ¨æœºå¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Motivation enhancement")**
+ **[è®°å¿†å¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Memory enhancement")**
+ **[æš—ç¤ºæ€§æŠ‘åˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Suggestibility suppression")**
+ **[æ€ç»´åŠ é€Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought acceleration")**
+ **[æ€ç»´ç»„ç»‡](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought organization")** - æ®æŠ¥é“ï¼Œè¿™ä¸ªæˆåˆ†æ¯”å…¶ä»–å…´å¥‹å‰‚æ›´çªå‡ºï¼Œè¿™å¯¼è‡´ä¸€äº›ç”¨æˆ·å°†å…¶ç”¨äºç”Ÿäº§æˆ–åŠŸèƒ½æ€§ç›®çš„ï¼Œè€Œä¸æ˜¯äº«ä¹ç›®çš„ã€‚
+ **[æ¸…é†’åº¦](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Wakefulness")**

### ä½“éªŒæŠ¥å‘Š

ç›®å‰æˆ‘ä»¬çš„[ä½“éªŒç´¢å¼•](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Experience index")ä¸­æ²¡æœ‰æè¿°è¿™ç§åŒ–åˆç‰©æ•ˆåº”çš„è½¶äº‹æŠ¥å‘Šã€‚å…¶ä»–çš„ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

* [Erowid ä½“éªŒåº“: 4-Fluoromethylphenidate](https://www.erowid.org/experiences/subs/exp_4Fluoromethylphenidate.shtml)


æ¯’æ€§å’Œä¼¤å®³æ½œåŠ›
---------------------------

- **è¿™ä¸ªæ¯’æ€§å’Œä¼¤å®³æ½œåŠ›éƒ¨åˆ†æ˜¯ä¸ª[å°ä½œå“ã€‚](#)**å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´ç”šè‡³**å±é™©çš„é”™è¯¯**ä¿¡æ¯ï¼ä½ å¯ä»¥å¸®å¿™[æ‰©å……æˆ–æ›´æ­£å®ƒã€‚](#)
*æ³¨æ„ï¼šå¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œè¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶å¹¶ä½¿ç”¨**[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")**å“¦ã€‚*

æ›´å¤šä¿¡æ¯ï¼š[ç ”ç©¶ç”¨åŒ–å­¦å“ Â§ æ¯’æ€§å’Œä¼¤å®³æ½œåŠ›](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md#Toxicity_and_harm_potential "Research chemicals")

å¨±ä¹æ€§ä½¿ç”¨ 4F-MPH çš„æ¯’æ€§å’Œé•¿æœŸå¥åº·å½±å“ä¼¼ä¹å°šæœªåœ¨ä»»ä½•ç§‘å­¦èƒŒæ™¯ä¸‹è¿›è¡Œç ”ç©¶ï¼Œç¡®åˆ‡çš„æ¯’æ€§å‰‚é‡å°šä¸æ¸…æ¥šã€‚è¿™æ˜¯å› ä¸º 4F-MPH æ˜¯ä¸€ç§[ç ”ç©¶ç”¨åŒ–å­¦å“](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Research chemical")ï¼Œäººç±»ä½¿ç”¨å†å²éå¸¸å°‘ã€‚å°è¯•è¿‡ 4F-MPH çš„äººçš„è½¶äº‹è¯æ®è¡¨æ˜ï¼Œä»…ä»…å°è¯•ä½åˆ°ä¸­ç­‰å‰‚é‡çš„è¯ç‰©æœ¬èº«å¹¶éå¸¸è°¨æ…åœ°ä½¿ç”¨ï¼Œä¼¼ä¹æ²¡æœ‰è´Ÿé¢çš„å¥åº·å½±å“ï¼ˆä½†ä¸èƒ½å®Œå…¨ä¿è¯ä»€ä¹ˆï¼‰ã€‚åœ¨æ¶ˆè´¹å‰ï¼Œåº”å§‹ç»ˆè¿›è¡Œ[ç‹¬ç«‹ç ”ç©¶](https://www.google.com)ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨çš„ã€‚

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¿™ç§è¯ç‰©æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")å‘¢ã€‚

### è€å—æ€§å’Œæˆç˜¾æ½œåŠ›

å°±å…¶è€å—æ€§è€Œè¨€ï¼Œ4F-MPH å¯ä»¥è¿ç»­å¤šå¤©é•¿æ—¶é—´ä½¿ç”¨ï¼Œä½†ç¡®å®å­˜åœ¨æ€¥æ€§è€å—æ€§ï¼Œå¹¶ä¸”éšç€é‡å¤çš„é•¿æœŸä½¿ç”¨è€Œé€æ¸å»ºç«‹ã€‚è¿™å¯¼è‡´ç”¨æˆ·éœ€è¦å¢åŠ å‰‚é‡æ‰èƒ½è¾¾åˆ°ç›¸åŒçš„æ•ˆæœã€‚æ®æŠ¥é“ï¼Œè€å—æ€§çš„å»ºç«‹æ¯”[å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")è¦å¿«ã€‚

ç”±äºç¼ºä¹æ˜¾è‘—çš„è€å—æ€§ã€æ¬£å¿«æ•ˆæœä»¥åŠå¯¹[å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")è½¬è¿è›‹ç™½çš„ä½œç”¨ï¼Œ4F-MPH çš„æ»¥ç”¨æ½œåŠ›ä¸[è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")æˆ–[MDMA](/è¯ç‰©/MDMA.md "MDMA")ç›¸å½“ã€‚

### å±é™©è¯ç‰©è”ç”¨

***è­¦å‘Šï¼š*** *è®¸å¤šç²¾ç¥æ´»æ€§ç‰©è´¨å•ç‹¬ä½¿ç”¨æ—¶ç›¸å¯¹å®‰å…¨ï¼Œä½†ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶å¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨åˆ—å‡ºäº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…å«æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*è¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com), [DuckDuckGo](https://www.duckduckgo.com), [PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨çš„ã€‚ä¸‹åˆ—çš„ä¸€äº›ç›¸äº’ä½œç”¨ä¸»è¦æ¥è‡ª [TripSit](https://combo.tripsit.me)ã€‚*

* **[25x-NBOMe](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md "25x-NBOMe") & [25x-NBOH](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md "25x-NBOH")** - 25x åŒ–åˆç‰©å…·æœ‰é«˜åº¦åˆºæ¿€æ€§ï¼Œå¯¹èº«ä½“æœ‰å¾ˆå¤§è´Ÿæ‹…ã€‚åº”ä¸¥æ ¼é¿å…ä¸ 4F-MPH è”ç”¨ï¼Œå› ä¸ºå­˜åœ¨è¿‡åº¦[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md "Stimulation")å’Œå¿ƒè„è´Ÿæ‹…çš„é£é™©ã€‚è¿™å¯èƒ½å¯¼è‡´[è¡€å‹å‡é«˜](/è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")ã€[è¡€ç®¡æ”¶ç¼©](/è¯æ•ˆ/è¡€ç®¡æ‰©å¼ .md "Vasoconstriction")ï¼ˆæ³¨ï¼šé“¾æ¥åŒä¸Šï¼‰ã€ææ…Œå‘ä½œã€[æ€ç»´å¾ªç¯](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought loops")ã€[ç™«ç—«å‘ä½œ](/è¯æ•ˆ/ç™«ç—«å‘ä½œ.md "Seizures")ï¼Œæç«¯æƒ…å†µä¸‹ç”šè‡³å¯¼è‡´å¿ƒåŠ›è¡°ç«­ã€‚
* **[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md "Alcohol")** - å°†é…’ç²¾ä¸[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")æ··åˆå¯èƒ½å¾ˆå±é™©ï¼Œå› ä¸ºå­˜åœ¨æ„å¤–è¿‡åº¦ä¸­æ¯’çš„é£é™©ã€‚å…´å¥‹å‰‚ä¼šæ©ç›–é…’ç²¾çš„[æŠ‘åˆ¶](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Depressant")ä½œç”¨ï¼Œè€Œå¤§å¤šæ•°äººæ˜¯ç”¨è¿™ç§æ„Ÿè§‰æ¥è¯„ä¼°è‡ªå·±çš„ä¸­æ¯’ç¨‹åº¦çš„ã€‚ä¸€æ—¦å…´å¥‹å‰‚æ¶ˆé€€ï¼Œ[æŠ‘åˆ¶](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Depressant")ä½œç”¨å°†ä¸å†å—é˜»ï¼Œè¿™å¯èƒ½å¯¼è‡´æ–­ç‰‡å’Œä¸¥é‡çš„[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md "Respiratory depression")ã€‚å¦‚æœæ··åˆä½¿ç”¨ï¼Œç”¨æˆ·åº”ä¸¥æ ¼é™åˆ¶è‡ªå·±æ¯å°æ—¶åªå–ä¸€å®šé‡çš„é…’ç²¾å–µã€‚
* **[å³ç¾æ²™èŠ¬](/è¯ç‰©/å³ç¾æ²™èŠ¬.md "DXM")** - åº”é¿å…ä¸å³ç¾æ²™èŠ¬è”ç”¨ï¼Œå› ä¸ºå®ƒå¯¹[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")å†æ‘„å–æœ‰æŠ‘åˆ¶ä½œç”¨ã€‚ä¸è¡€æ¸…ç´ é‡Šæ”¾å‰‚ï¼ˆ[MDMA](/è¯ç‰©/MDMA.md "MDMA")ã€[ç‰¹æˆŠé…®](/è¯ç‰©/ç”²å¡è¥¿é…®.md "Methylone")ï¼ˆæ³¨ï¼šæ­¤å¤„Methyloneæš‚æ— å¯¹åº”æ–‡ä»¶ï¼ŒæŒ‡å‘ç”²å¡è¥¿é…®æˆ–ä¸åŠ é“¾æ¥ï¼Œæš‚æŒ‡å‘ç”²å¡è¥¿é…®ç±»ï¼‰ã€[ç”²æ°§éº»é»„é…®](/è¯ç‰©/4-MMC.md "Mephedrone")ç­‰ï¼‰è”ç”¨æ—¶ï¼Œ[ææ…Œå‘ä½œ](/è¯æ•ˆ/ç„¦è™‘.md "Panic attacks")å’Œé«˜è¡€å‹å±è±¡æˆ–[è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")çš„é£é™©ä¼šå¢åŠ ã€‚è¯·ä»”ç»†ç›‘æµ‹è¡€å‹å¹¶é¿å…å‰§çƒˆçš„èº«ä½“æ´»åŠ¨ã€‚
* **[MDMA](/è¯ç‰©/MDMA.md "MDMA")** - å½“å­˜åœ¨å…¶ä»–[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")æ—¶ï¼ŒMDMA çš„ä»»ä½•ç¥ç»æ¯’æ€§ä½œç”¨éƒ½å¯èƒ½ä¼šå¢åŠ ã€‚è¿˜å­˜åœ¨è¡€å‹è¿‡é«˜å’Œå¿ƒè„è´Ÿæ‹…ï¼ˆå¿ƒè„æ¯’æ€§ï¼‰çš„é£é™©ã€‚
* **[MXE](/è¯ç‰©/MXE.md "MXE")** - ä¸€äº›æŠ¥å‘Šè¡¨æ˜ä¸ MXE è”ç”¨å¯èƒ½ä¼šå±é™©åœ°å¢åŠ è¡€å‹ï¼Œå¹¶å¢åŠ [èºç‹‚](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mania")å’Œ[ç²¾ç¥ç—…](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Psychosis")çš„é£é™©ã€‚
* **[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md "Dissociatives")** - è¿™ä¸¤ç±»è¯ç‰©éƒ½æœ‰å¼•èµ·[å¦„æƒ³](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Delusions")ã€[èºç‹‚](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mania")å’Œ[ç²¾ç¥ç—…](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Psychosis")çš„é£é™©ï¼Œè”ç”¨æ—¶è¿™äº›é£é™©å¯èƒ½ä¼šæˆå€å¢åŠ ã€‚
* **[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")** - 4F-MPH ä¸å…¶ä»–[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")å¦‚[å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md "Cocaine")è”ç”¨å¯èƒ½æ˜¯å±é™©çš„ï¼Œå› ä¸ºå®ƒä»¬ä¼šä½¿[å¿ƒç‡](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")å’Œ[è¡€å‹](/è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")å‡é«˜åˆ°å±é™©æ°´å¹³ã€‚
* **[æ›²é©¬å¤š](/è¯ç‰©/æ›²é©¬å¤š.md "Tramadol")** - å·²çŸ¥æ›²é©¬å¤šä¼šé™ä½ç™«ç—«å‘ä½œé˜ˆå€¼[\[8\]](#cite_note-8)ï¼Œä¸å…´å¥‹å‰‚è”ç”¨å¯èƒ½ä¼šè¿›ä¸€æ­¥å¢åŠ è¿™ç§é£é™©ã€‚
* **[å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md "MAOIs")** - è¿™ç§ç»„åˆå¯èƒ½ä¼šå°†å¤šå·´èƒºç­‰ç¥ç»é€’è´¨çš„é‡å¢åŠ åˆ°å±é™©ç”šè‡³è‡´å‘½çš„æ°´å¹³ã€‚ä¾‹å­åŒ…æ‹¬[å™åˆ©äºšèŠ¸é¦™](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Syrian rue")ï¼ˆæ³¨ï¼šæš‚æ— å•ç‹¬æ¡ç›®ï¼ŒæŒ‡å‘åˆ†ç±»ï¼‰ã€[*å¡çš®æœ¨*](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‡´å¹»å‰‚.md "Banisteriopsis caapi")ï¼ˆæ³¨ï¼šåŒä¸Šï¼‰å’Œä¸€äº›[æŠ—æŠ‘éƒè¯](/è¯ç‰©/ä¸å»ºè®®ä½¿ç”¨çš„è¯ç‰©.md "Antidepressants")ã€‚[\[9\]](#cite_note-9)


æ³•å¾‹åœ°ä½
------------

| ![Handcuffs-300px.png](/æ–‡ä»¶/Handcuffs-300px.png) | **è¿™ä¸ªæ³•å¾‹éƒ¨åˆ†æ˜¯ä¸ª[å°ä½œå“](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "Stub")ã€‚**<br>*å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´æˆ–é”™è¯¯çš„ä¿¡æ¯ã€‚ä½ å¯ä»¥å¸®å¿™[æ‰©å……å®ƒ](# "Expanding it")ã€‚* |
| --- | --- |

* **å¾·å›½**: æˆªè‡³2016å¹´11æœˆ26æ—¥ï¼Œ4-æ°Ÿå“Œç”²é…¯æ ¹æ® NpSG (*æ–°ç²¾ç¥æ´»æ€§ç‰©è´¨æ³•*)[\[10\]](#cite_note-10) å—åˆ°ç®¡åˆ¶ã€‚[\[11\]](#cite_note-11)ï¼Œä½†åœ¨2022å¹´9æœˆè¢«æ„å¤–åˆæ³•åŒ–ã€‚ç›®å‰è¢«è®¤ä¸ºå†æ¬¡åˆæ³•å•¦ã€‚
* **æ„å¤§åˆ©**: 4F-MPH æ˜¯ä¸€çº§ç®¡åˆ¶ç‰©è´¨ï¼ŒæŒæœ‰ã€ç”Ÿäº§ã€é”€å”®å’Œè´­ä¹°éƒ½æ˜¯éæ³•çš„ã€‚
* **ç‘å£«**: 4F-MPH æ˜¯ Verzeichnis E ä¸­ç‰¹åˆ«æŒ‡å®šçš„å—æ§ç‰©è´¨ã€‚[\[12\]](#cite_note-12)
* **åœŸè€³å…¶:** 4F-MPH è¢«å½’ç±»ä¸ºè¯ç‰©ï¼ŒæŒæœ‰ã€ç”Ÿäº§ã€ä¾›åº”æˆ–è¿›å£éƒ½æ˜¯éæ³•çš„ã€‚[\[13\]](#cite_note-13)
* **è‹±å›½**: æˆªè‡³2017å¹´5æœˆ31æ—¥ï¼Œ4-æ°Ÿå“Œç”²é…¯åœ¨è‹±å›½æ˜¯Bç±»è¯ç‰©ï¼ŒæŒæœ‰ã€ç”Ÿäº§æˆ–ä¾›åº”éƒ½æ˜¯éæ³•çš„ã€‚[\[14\]](#cite_note-14)
* **ç¾å›½**: 4-æ°Ÿå“Œç”²é…¯åœ¨é˜¿æ‹‰å·´é©¬å·æ˜¯ä¸€çº§ç®¡åˆ¶ç‰©è´¨ã€‚[\[15\]](#cite_note-15)


å¦è§
--------

* [è´Ÿè´£ä»»çš„ç”¨è¯](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible use")
* [ç­–åˆ’è¯](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Designer drug")
* [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")
* [å“Œç”²é…¯](/è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")
* [4F-EPH](/è¯ç‰©/4F-EPH.md "4F-EPH")ï¼ˆæ³¨ï¼šå‡è®¾å­˜åœ¨è¯¥æ–‡ä»¶ï¼Œæˆ–åº”æ–°å»ºï¼‰


å¤–éƒ¨é“¾æ¥
--------------

* [4F-MPH (Wikipedia)](https://en.wikipedia.org/wiki/4-Fluoromethylphenidate)
* [4F-MPH (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=630)
* [4F-MPH (Bluelight)](http://www.bluelight.org/vb/threads/770658-4-Fluoromethylphenidate-(4F-MPH))
* [4F-MPH (UK Chemical Research)](https://www.ukchemicalresearch.org/Thread-4-Fluoromethylphenidate-4F-MPH)


å‚è€ƒæ–‡çŒ®
----------

1. [â†‘](#cite_ref-1) <http://www.bluelight.org/vb/threads/770658-4-Fluoromethylphenidate-(4F-MPH)>
2. [â†‘](#cite_ref-2) Deutsch, H. M., Shi, Q., Gruszecka-Kowalik, E., Schweri, M. M. (15 March 1996). ["Synthesis and Pharmacology of Potential Cocaine Antagonists. 2. Structureâˆ’Activity Relationship Studies of Aromatic Ring-Substituted Methylphenidate Analogs"](https://pubs.acs.org/doi/10.1021/jm950697c). *Journal of Medicinal Chemistry*. **39** (6): 1201â€“1209. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1021/jm950697c](//doi.org/10.1021%2Fjm950697c). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0022-2623](//www.worldcat.org/issn/0022-2623).Â 
3. [â†‘](#cite_ref-3) Schweri, M. M., Deutsch, H. M., Massey, A. T., Holtzman, S. G. (May 2002). "Biochemical and behavioral characterization of novel methylphenidate analogs". *The Journal of Pharmacology and Experimental Therapeutics*. **301** (2): 527â€“535. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1124/jpet.301.2.527](//doi.org/10.1124%2Fjpet.301.2.527). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0022-3565](//www.worldcat.org/issn/0022-3565).Â 
4. [â†‘](#cite_ref-4) Davies, H. M. L., Hopper, D. W., Hansen, T., Liu, Q., Childers, S. R. (5 April 2004). "Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites". *Bioorganic & Medicinal Chemistry Letters*. **14** (7): 1799â€“1802. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.bmcl.2003.12.097](//doi.org/10.1016%2Fj.bmcl.2003.12.097). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0960-894X](//www.worldcat.org/issn/0960-894X).Â 
5. [â†‘](#cite_ref-5) Misra, M., Shi, Q., Ye, X., Gruszecka-Kowalik, E., Bu, W., Liu, Z., Schweri, M. M., Deutsch, H. M., Venanzi, C. A. (15 October 2010). "Quantitative structure-activity relationship studies of threo-methylphenidate analogs". *Bioorganic & Medicinal Chemistry*. **18** (20): 7221-7238. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.bmc.2010.08.034](//doi.org/10.1016%2Fj.bmc.2010.08.034). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1464-3391](//www.worldcat.org/issn/1464-3391).Â 
6. [â†‘](#cite_ref-6) Singh, S. (1 March 2000). ["Chemistry, Design, and Structureâˆ’Activity Relationship of Cocaine Antagonists"](https://pubs.acs.org/doi/10.1021/cr9700538). *Chemical Reviews*. **100** (3): 925â€“1024. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1021/cr9700538](//doi.org/10.1021%2Fcr9700538). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0009-2665](//www.worldcat.org/issn/0009-2665).Â 
7. [â†‘](#cite_ref-7) McLaughlin, G., Morris, N., Kavanagh, P. V., Power, J. D., Dowling, G., Twamley, B., Oâ€™Brien, J., Hessman, G., Murphy, B., Walther, D., Partilla, J. S., Baumann, M. H., Brandt, S. D. (March 2017). ["Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (Â±)- threo and (Â±)- erythro diastereomers: Analytical characterization and pharmacological evaluation of 4-fluoromethylphenidate"](https://onlinelibrary.wiley.com/doi/10.1002/dta.2167). *Drug Testing and Analysis*. **9** (3): 347â€“357. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/dta.2167](//doi.org/10.1002%2Fdta.2167). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1942-7603](//www.worldcat.org/issn/1942-7603).Â 
8. [â†‘](#cite_ref-8) Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". *Journal of Medical Toxicology*. **5** (2): 63â€“67. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/BF03161089](//doi.org/10.1007%2FBF03161089). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number")Â [1937-6995](//www.worldcat.org/issn/1937-6995). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1556-9039](//www.worldcat.org/issn/1556-9039). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC")Â [163567183](//www.worldcat.org/oclc/163567183).Â 
9. [â†‘](#cite_ref-9) Gillman, P. K. (2005). ["Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity"](https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext). *British Journal of Anaesthesia*. **95** (4): 434â€“441. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/bja/aei210](//doi.org/10.1093%2Fbja%2Faei210)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number")Â [1471-6771](//www.worldcat.org/issn/1471-6771). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0007-0912](//www.worldcat.org/issn/0007-0912). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC")Â [01537271](//www.worldcat.org/oclc/01537271). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier")Â [16051647](//www.ncbi.nlm.nih.gov/pubmed/16051647).Â 
10. [â†‘](#cite_ref-10) ["Anlage NpSG"](https://www.gesetze-im-internet.de/npsg/anlage.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 23, 2019.Â 
11. [â†‘](#cite_ref-11) ["Gesetz zur BekÃ¤mpfung der Verbreitung neuer psychoaktiver Stoffe"](https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518) (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 23, 2019.Â 
12. [â†‘](#cite_ref-12) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.Â 
13. [â†‘](#cite_ref-13) CumhurbaÅŸkanÄ± KararÄ± Karar SayÄ±sÄ± : 1335 | <https://resmigazete.gov.tr/eskiler/2019/07/20190720-19.pdf>
14. [â†‘](#cite_ref-14) [*The Misuse of Drugs Act 1971 (Amendment) Order 2017*](https://www.legislation.gov.uk/uksi/2017/634/made)Â 
15. [â†‘](#cite_ref-15) [*Alabama SB333, 2014, Regular Session*](https://legiscan.com/AL/text/SB333/id/988417)